SEC Tracker
Get the app

Alpine Immune Sciences

OrbiMed Genesis Master Fund (Shareholder) plans to sell 161,216 shares, about $3.3M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Dec 27, 2023
  2. Broker: Themis Trading LLC
  3. Shares acquired by: Purchase

All of OrbiMed Genesis Master Fund's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 162,576 shares at $19.96 on Dec 27, 2023 ยท Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Alpine Immune Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.